Skip to content

GRAL

GRAIL, Inc.

NASDAQ · USHealthcareMedical - Diagnostics & Research
$68.91-5.11%

Price as of Jul 20, 2026

GRAL growth

GRAIL, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue
+19.4%
EBITDA
+36.3%
EBIT
+74.3%
EPS
+83.0%
Free cash flow
+37.7%
Operating cash flow
+37.4%

Forward estimates

Revenue
+25.8%
EBITDA
+41.8%
EPS
-4.8%

Three-year CAGR

Revenue
+38.4%
EBITDA
+38.0%
EBIT
+75.6%
Net income
+79.9%
EPS
+82.5%
Free cash flow
+48.7%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.